Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04065490

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

Dry Age-related Macular Degeneration Clinical Trial

Official title:
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)

Clinical Trial Summary

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.

Clinical Trial Description

This study is a double-masked, sham-controlled, parallel design prospective, multi-site study on the use of photobiomodulation (PBM) as a treatment for visual impairment in subjects with dry AMD. Subjects will receive repeated sham or PBM treatments at several time-points throughout the 2-year study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04065490
Study type Interventional
Source LumiThera, Inc.
Contact
Status Active, not recruiting
Phase N/A
Start date September 1, 2019
Completion date June 1, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03046407 - Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells Phase 1/Phase 2
Active, not recruiting NCT04566445 - HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Phase 2
Recruiting NCT04339764 - Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536752 - QA102 Phase II Study in Subjects With Dry AMD Phase 2
Recruiting NCT06351605 - A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)
Recruiting NCT06229665 - Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) Phase 2/Phase 3
Completed NCT01002950 - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy Phase 2
Active, not recruiting NCT03333954 - Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration N/A
Completed NCT05667688 - Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 Phase 1
Completed NCT01379560 - A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration Phase 2
Completed NCT03144999 - Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 Phase 1
Withdrawn NCT04511936 - Microcurrent Stimulation for Dry Age-related Macular Degeneration N/A
Withdrawn NCT04358471 - Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) Phase 2
Terminated NCT04643886 - A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration Phase 2
Not yet recruiting NCT05418231 - Observation of the Natural Course of Age-related Macular Degeneration
Recruiting NCT00926861 - Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD N/A
Active, not recruiting NCT04437368 - EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Phase 2
Active, not recruiting NCT03894020 - GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
Not yet recruiting NCT04875234 - Vision Improvement for Legally Blind Dry AMD Patients
Recruiting NCT02755428 - Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases Phase 1/Phase 2